30.76
0.05 (0.16%)
| Previous Close | 30.71 |
| Open | 30.68 |
| Volume | 476,113 |
| Avg. Volume (3M) | 618,972 |
| Market Cap | 1,716,854,016 |
| Price / Earnings (TTM) | 23.30 |
| Price / Earnings (Forward) | 20.16 |
| Price / Sales | 2.71 |
| Price / Book | 1.75 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | 9.27% |
| Operating Margin (TTM) | -4.67% |
| Diluted EPS (TTM) | 1.11 |
| Quarterly Revenue Growth (YOY) | 4.30% |
| Quarterly Earnings Growth (YOY) | 1,204.50% |
| Total Debt/Equity (MRQ) | 3.13% |
| Current Ratio (MRQ) | 2.44 |
| Operating Cash Flow (TTM) | 164.15 M |
| Levered Free Cash Flow (TTM) | 138.80 M |
| Return on Assets (TTM) | 2.76% |
| Return on Equity (TTM) | 6.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Supernus Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 4.87% |
| % Held by Institutions | 109.32% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Jun 2025 | Announcement | Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio |
| 29 May 2025 | Announcement | Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals |
| 28 May 2025 | Announcement | Supernus Announces Paragraph IV ANDA Filings for Qelbree® |
| 28 May 2025 | Announcement | Supernus to Participate in the 2025 Jefferies Global Healthcare Conference |
| 20 May 2025 | Announcement | Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals |
| 06 May 2025 | Announcement | Supernus Announces First Quarter 2025 Financial Results |
| 23 Apr 2025 | Announcement | Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |